Why is anticoagulation with warfarin (Coumadin) recommended for patients with mitral valve disease or after mitral valve replacement?

Anticoagulation with Warfarin in Mitral Valve Disease

Warfarin (Coumadin) is indicated for mitral valve disease primarily to prevent thromboembolic stroke and systemic embolism, which occur at substantially higher rates with mitral pathology compared to aortic valve disease due to left atrial blood stasis, atrial fibrillation, and left atrial enlargement.

Why Anticoagulation is Required

The mitral valve's anatomic position creates unique thrombotic risk:

• Left atrial stasis: Mitral stenosis and mitral valve disease cause elevated left atrial pressures and blood stasis, creating a prothrombotic environment
• Atrial fibrillation: Present in 40-75% of patients with rheumatic mitral stenosis, dramatically increasing stroke risk to approximately 4% per year 1, 2
• Higher embolic rates: Mitral bioprostheses have thromboembolic rates of 2.4% per patient-year versus 1.9% for aortic prostheses 3
• Left atrial enlargement and thrombus formation: Even without AF, severe mitral stenosis with left atrial dimension ≥55 mm carries significant embolic risk 1

Specific Indications and Target INR

Native Mitral Valve Disease

For mitral stenosis:

• With prior embolic event: Anticoagulation is mandatory even in sinus rhythm (Class I, Level B) 1
• With left atrial thrombus: Anticoagulation is mandatory (Class I, Level B) 1
• With atrial fibrillation: Long-term anticoagulation is recommended 4
• Severe stenosis with LA ≥55 mm: Anticoagulation may be considered even if asymptomatic (Class IIb, Level B) 1

Target INR: 2.0-3.0 4

Mechanical Mitral Valve Replacement

All mechanical mitral valves require lifelong anticoagulation with warfarin to target INR 2.5-3.5 (range 2.5-3.5) plus low-dose aspirin 1, 5, 4. This higher INR target compared to aortic mechanical valves (INR 2.0-3.0) reflects the substantially greater thrombotic risk in the mitral position.

Bioprosthetic Mitral Valve Replacement

First 3 months post-implantation:

• Warfarin to target INR 2.0-3.0 is reasonable for all patients (Class IIa, Level C) 1, 3
• This addresses the heightened early thrombotic risk (1.5% stroke rate within 30 days) until the valve is fully endothelialized 3

Beyond 3 months:

• With risk factors (AF, previous thromboembolism, LV dysfunction): Continue warfarin indefinitely, target INR 2.0-3.0 (Class I, Level C) 5, 4
• Without risk factors and sinus rhythm: May discontinue warfarin and use low-dose aspirin alone (Class I, Level C) 5

After Mitral Valve Repair

This remains the most controversial area with substantial practice variation 6. However, emerging evidence supports anticoagulation:

• A 2016 Danish registry study of 2,188 patients found warfarin use after mitral valve repair was associated with 72% lower risk of death/stroke at 3 months (HR 0.28,95% CI 0.13-0.62) without excess bleeding 7
• A 2020 retrospective study of 1,097 patients showed warfarin reduced composite bleeding/thromboembolic complications (OR 0.29,95% CI 0.13-0.64) and improved 10-year survival (92% vs 85%) 8

Recommendation: Consider warfarin (INR 2.0-3.0) for 3 months after isolated mitral valve repair, particularly given high rates of postoperative atrial fibrillation and preventable strokes 7, 8.

Critical Distinctions from Aortic Valve Disease

The evidence for mitral valve anticoagulation is frequently extrapolated from aortic valve studies, despite fundamentally different thrombotic risk profiles 9. The mitral position carries:

• Higher baseline embolic risk due to left atrial pathology
• Greater impact of atrial fibrillation
• More pronounced benefit from anticoagulation even in sinus rhythm

Common Pitfalls

1. Undertreating mitral stenosis with AF: Even "mild" mitral stenosis with AF requires anticoagulation 4
2. Using lower INR targets for mechanical mitral valves: The target is 2.5-3.5, not 2.0-3.0 4
3. Stopping anticoagulation too early after bioprosthetic mitral valve: The first 3-6 months carry highest risk 3
4. Assuming mitral valve repair doesn't require anticoagulation: Recent evidence suggests 3-month anticoagulation reduces complications 7, 8

The fundamental principle: mitral valve pathology creates left atrial stasis and thrombotic risk that warrants more aggressive anticoagulation than comparable aortic valve disease.